The New Sirolimus Eluting Balloons Are Also Effective

The technological development of drug eluting stents has allowed us to treat increasingly complex patients, with around 10% stenosis and using more, and longer stents. 

stent-liberador-drogas-sirolimus-everolimus

This situation generates a great challenge: keep using stents or use paclitaxel coated balloons (PCB). At present, there are sirolimus drug coated balloons (SCB), but we do not have enough data to determine which one performs better. 

This is the first randomized study to compare SCB against PCB in the treatment of instent restenosis.

The study included 101 patients: 50 received PCI with SCB and 51 with PCB.

Primary end point at 6 months was Late Lumen Loss (LLL) by quantitative angiography.

There were no differences between populations. 80% were men, 57% diabetic and 35% were admitted with unstable angina. Neither were there angiographic differences after procedure. 

Read also: Use of OCT FFR on ACS Clinical Outcomes.

After a 6-month follow-up, there were no differences in primary end point (LLL 0.25±0.57 mm in PCB vs 0.26±0.60 mm in SCB).

After 12 months, there were no differences in death, MI, ischemia driven revascularization or restenosis. 

Conclusion

This is the first study to compare the new sirolimus coated balloon against paclitaxel coated balloons. This study has shown similar angiographic and clinical evolution in the treatment of instent restenosis.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions.

Reference: Bruno Scheller,et al. Circ Cardiovasc Interv. 2022;15:e012305. DOI:10.1161/CIRCINTERVENTIONS.122.012305.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...